Heat Biologics cancer news
Heat will reduce headcount by 6 (22%) to 21 to save cash and focus on advancing HS-410 and HS-110 to data readouts in 4Q16. The company also will reduce compensation for its remaining leadership team and announced the voluntary resignation of two directors.
HS-410 is in Phase II testing to treat non-muscle invasive bladder cancer. The product is a bladder cancer cell line genetically modified using Immune Pan-Antigen Cytotoxic Therapy (ImPACT) technology to secrete bladder cancer antigens bound to a heat shock 90 kDa protein beta 1 ( Hsp90B1; GP96; GRP94). Heat also will reduce operating expenses by advancing only the eight patients enrolled in its Phase 1b clinical trial of HS-110 in non-small cell lung cancer (NSCLC). The trial was initially planned to enroll 18 patients. The product is a vaccine comprising lung cancer cells engineered using ImPACT technology to secrete antigens bound to an Hsp90B1 adjuvant. ...